Literature DB >> 27234600

Polymorphisms of TGFβ-1 and TGFBR2 in relation to coronary artery disease in a Chinese population.

Minjun Yang1, Min Zhu2, Lijiang Tang3, Huanhuan Zhu1, Yifei Lu1, Baohui Xu4, Jianjun Jiang5, Xiaofeng Chen6.   

Abstract

BACKGROUND AND AIM: TGF-β1 has been previously reported to be involved in the pathogenesis of atherosclerosis. The aim of the present study was to assess whether functional gene polymorphisms of TGF-β1 and its key receptor TGF-β receptor type II (TGFBR2) contribute as risk factors to the onset and severity of atherosclerotic coronary artery disease (CAD). DESIGN AND METHODS: A total of 605 patients who underwent angiography for suspected CAD were prospectively recruited to this study. Coronary stenosis severity was assessed by the number of narrowed coronary vessels and the Gensini score. Among them, 502 patients had documented CAD, and 103 patients without documented CAD served as non-CAD controls. All patients were genotyped for one TGF-β1 polymorphism (rs1800470 (+T29C)) and two TGFBR2 polymorphisms (rs6785385 (-3779A/G), rs764522 (-1444C/G)) by polymerase chain reaction-restriction fragment length polymorphism and confirmed by direct sequencing.
RESULTS: No significant difference in the frequency for either polymorphism was found between CAD and control patients. Neither TGFBR2 rs6785385 (-3779A/G) nor rs764522 (-1444C/G) gene polymorphisms were associated with the severity of CAD (P>0.05). In male CAD patients, polymorphisms at TGF-β1 rs1800470 (+T29C) were, however, associated with the severity of CAD. The T allele frequency was significantly and positively correlated with the number of narrowed coronary arteries (three or more vessels: 49.3%, two vessels: 44.1%, one vessel: 36.9%) (P=0.039). Gensini scores in patients with the TT, CT, and CC genotype were 34.33±2.23, 32.06±4.79, and 26.90±3.83, respectively (P<0.05). In multiple linear regression analysis, the T allele of TGF-β1 polymorphism was independently correlated with the Gensini score (β=0.131).
CONCLUSION: TGF-β1 T29C gene polymorphism may be associated with severity of CAD in male patients. TGFBR2 polymorphisms may not determine the genetic susceptibility to CAD.
Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Coronary artery disease; Gene mutations; Transforming growth factor beta

Mesh:

Substances:

Year:  2016        PMID: 27234600     DOI: 10.1016/j.clinbiochem.2016.05.022

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  The Relationship between VEGFA and TGFB1 Polymorphisms and Target Lesion Revascularization after Elective Percutaneous Coronary Intervention.

Authors:  Tadeusz Osadnik; Andrzej Lekston; Kamil Bujak; Joanna Katarzyna Strzelczyk; Lech Poloński; Mariusz Gąsior
Journal:  Dis Markers       Date:  2017-07-24       Impact factor: 3.434

2.  A genetic risk score is differentially associated with migraine with and without aura.

Authors:  Jessica Mwinyi; Helgi B Schiöth; Claudia Pisanu; Martin Preisig; Enrique Castelao; Jennifer Glaus; Giorgio Pistis; Alessio Squassina; Maria Del Zompo; Kathleen R Merikangas; Gérard Waeber; Peter Vollenweider
Journal:  Hum Genet       Date:  2017-06-27       Impact factor: 4.132

3.  The comparison of serum TGF-beta levels and associated polymorphisms in patients with coronary artery ectasia and normal coronary artery.

Authors:  Özgür Selim Ser; Gökhan Çetinkal; Onur Kiliçarslan; Yalçın Dalgıç; Servet Batit; Kudret Keskin; Gulçin Özkara; Ezgi Irmak Aslan; Hülya Yilmaz Aydoğan; Ahmet Yıldız; Zerrin Yiğit
Journal:  Egypt Heart J       Date:  2021-03-31

4.  Association of Multiple Genetic Variants with the Extension and Severity of Coronary Artery Disease.

Authors:  Simone Cristina Pinto Matheus Fischer; Simone Pires Pinto; Lívia Campos do Amaral Silva Lins; Henrique Tria Bianco; Carlos Manoel de Castro Monteiro; Luiz Fernando Muniz Pinheiro; Francisco Antonio Helfenstein Fonseca; Maria Cristina de Oliveira Izar
Journal:  Arq Bras Cardiol       Date:  2018-02-01       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.